< Terug naar vorige pagina
Pan-cancer pharmacogenetics : targeted sequencing panels or exome sequencing?
Tijdschriftbijdrage - Tijdschriftartikel
Aim:This study provides clinicians and researchers with an informed choice between current commercially available targeted sequencing panels and exome sequencing panels in the context of pan-cancer pharmacogenetics.Materials & methods:Nine contemporary commercially available targeted pan-cancer panels and the xGen Exome Research Panel v2 were investigated to determine to what extent they cover the pharmacogenetic variant-drug interactions in five available cancer knowledgebases, and the driver mutations and fusion genes in The Cancer Genome Atlas.Results:xGen Exome Research Panel v2 and TrueSight Oncology 500 target 71.0 and 68.9% of the pharmacogenetic interactions in the available knowledgebases, and 93.7 and 86.0% of the driver mutations in The Cancer Genome Atlas, respectively. All other studied panels target lower percentages.Conclusion:Exome sequencing outperforms pan-cancer targeted sequencing panels in terms of covered cancer pharmacogenetic variant-drug interactions and pharmacogenetic cancer variants.
Pagina's: 1073 - 1084
Jaar van publicatie:2020